TW200503690A - Pharmaceutical compositions of atorvastatin - Google Patents

Pharmaceutical compositions of atorvastatin

Info

Publication number
TW200503690A
TW200503690A TW093116894A TW93116894A TW200503690A TW 200503690 A TW200503690 A TW 200503690A TW 093116894 A TW093116894 A TW 093116894A TW 93116894 A TW93116894 A TW 93116894A TW 200503690 A TW200503690 A TW 200503690A
Authority
TW
Taiwan
Prior art keywords
atorvastatin
compositions
pharmaceutical composition
acceptable salt
wet granulated
Prior art date
Application number
TW093116894A
Other languages
English (en)
Inventor
Kenneth Craig Waterman
Michael Bruce Fergione
Barbara Alice Johnson
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of TW200503690A publication Critical patent/TW200503690A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pyrrole Compounds (AREA)
TW093116894A 2003-06-12 2004-06-11 Pharmaceutical compositions of atorvastatin TW200503690A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US47811903P 2003-06-12 2003-06-12

Publications (1)

Publication Number Publication Date
TW200503690A true TW200503690A (en) 2005-02-01

Family

ID=33551806

Family Applications (1)

Application Number Title Priority Date Filing Date
TW093116894A TW200503690A (en) 2003-06-12 2004-06-11 Pharmaceutical compositions of atorvastatin

Country Status (15)

Country Link
EP (1) EP1635814A1 (zh)
JP (1) JP2006527260A (zh)
KR (1) KR100814218B1 (zh)
CN (1) CN100434069C (zh)
AR (1) AR044774A1 (zh)
AU (1) AU2004246868B2 (zh)
BR (1) BRPI0411344A (zh)
CA (1) CA2465565A1 (zh)
CO (1) CO5650230A2 (zh)
MX (1) MXPA05013281A (zh)
NO (1) NO20060022L (zh)
NZ (1) NZ543337A (zh)
RU (1) RU2332211C2 (zh)
TW (1) TW200503690A (zh)
WO (1) WO2004110431A1 (zh)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
GB0613925D0 (en) 2006-07-13 2006-08-23 Unilever Plc Improvements relating to nanodispersions
EP2170294A1 (en) * 2007-06-25 2010-04-07 Pharmathen S.A. Improved pharmaceutical formulation containing an hmg-coa reductase inhibitor and method for the preparation thereof
CN102089016A (zh) * 2008-02-27 2011-06-08 托门医学股份公司 植入物及其制备方法
AU2009292615B2 (en) * 2008-09-17 2015-12-03 Mylan Inc. Granulates, process for preparing them and pharmaceutical products containing them
HUP1000299A2 (hu) 2010-06-08 2012-02-28 Nanoform Cardiovascular Therapeutics Ltd Nanostrukturált Atorvastatint, gyógyszerészetileg elfogadott sóit és kokristályait tartalmazó készítmény és eljárás elõállításukra
WO2013072770A2 (en) 2011-11-15 2013-05-23 Dr. Reddy's Laboratories Ltd. Pharmaceutical formulations comprising atorvastatin and glimepiride
CN104069078B (zh) * 2014-05-22 2019-06-11 西藏九瑞健康股份有限公司 阿托伐他汀钙药物组合物及其制备方法
SG10201900648SA (en) * 2014-07-25 2019-02-27 Novartis Ag Tablet formulation of 2-fluoro-n-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide
KR101658350B1 (ko) * 2015-02-06 2016-09-30 경성대학교 산학협력단 고지혈증 치료에 유용한 약학 조성물
EP3267977B1 (en) * 2015-03-12 2021-08-11 DuPont Nutrition USA, Inc. Solid dispersions
JPWO2017170858A1 (ja) 2016-03-31 2019-02-14 インターセプト ファーマシューティカルズ， インコーポレイテッド 溶出性に優れた経口製剤

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994016693A1 (en) * 1993-01-19 1994-08-04 Warner-Lambert Company Stable oral ci-981 formulation and process of preparing same
JPH06242003A (ja) * 1993-02-12 1994-09-02 Nkk Corp 鉄鋼中のアルミナの粒度測定方法
JP3014040B2 (ja) * 1996-10-30 2000-02-28 信久 川野 食物繊維パン及びその製造法
EP2382970B1 (en) * 2000-04-10 2013-01-09 Teva Pharmaceutical Industries, Ltd. Stable Pharmaceutical Compositions Containing 7-Substituted-3,5-Dihydroxyheptanoic Acids or 7-Substituted-3,5-Dihydroxyheptenoic Acids
US6242003B1 (en) * 2000-04-13 2001-06-05 Novartis Ag Organic compounds
EP1226818A1 (en) * 2001-01-26 2002-07-31 Pfizer Products Inc. Pharmaceutical dosage forms with enhanced cohesive and compressibility properties
SI20848A (sl) * 2001-03-14 2002-10-31 Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D. Farmacevtska formulacija, ki vsebuje atorvastatin kalcij

Also Published As

Publication number Publication date
CN1805741A (zh) 2006-07-19
CO5650230A2 (es) 2006-06-30
NO20060022L (no) 2006-01-03
CN100434069C (zh) 2008-11-19
NZ543337A (en) 2008-03-28
AR044774A1 (es) 2005-10-05
RU2005136745A (ru) 2006-07-27
AU2004246868B2 (en) 2008-01-17
RU2332211C2 (ru) 2008-08-27
EP1635814A1 (en) 2006-03-22
BRPI0411344A (pt) 2006-07-11
AU2004246868A1 (en) 2004-12-23
KR100814218B1 (ko) 2008-03-17
MXPA05013281A (es) 2006-03-09
CA2465565A1 (en) 2004-12-12
WO2004110431A1 (en) 2004-12-23
KR20060020666A (ko) 2006-03-06
JP2006527260A (ja) 2006-11-30

Similar Documents

Publication Publication Date Title
NO20060022L (no) Stabile sammensetninger av atorvastatin fremstilt ved vat granulering
WO2001085257A3 (en) Opioid antagonist compositions and dosage forms
EP2305251A3 (en) Pharmaceutical compositions comprising clavulanic acid or derivative thereof for the treatment of sexual disorder
MA27523A1 (fr) Formulation retard a liberation controlee
TW200509905A (en) Pharmaceutical compositions of atorvastatin
NO20060149L (no) Farmasoytiske forbindelser av atorvastatin
WO2002030462A3 (en) Hedgehog antagonists, methods and uses related thereto
TNSN01130A1 (fr) Formulations a liberation prolongee pour des secretagogues d'hormone de croissance
AU2721402A (en) Anilinopyrimidine derivatives as jnk pathway inhibitors and compositions and methods related thereto
MY144992A (en) Substituted 1,2,3,4-tetrahydroisoquinoline derivatives.
SE0300010D0 (sv) Novel Compounds
DE602004026053D1 (zh)
BG66087B1 (bg) Хинолинонови производни като тирозин киназни инхибитори
WO2006044362A3 (en) N-sulfonylpiperidine cannabinoid receptor 1 antagonists
WO2006118948A3 (en) Therapeutic compositions
AP1424A (en) 2-Phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole in combination with estrogens.
WO2001035950A3 (en) Benzamide therapeutics and methods for treating inflammatory bowel disease
ATE272628T1 (de) Substituierte gamma-phenyl-delta-lactone und deren analoge, und ihre verwendungen
CA2378613A1 (en) Selective iglur5 receptor antagonists for the treatment of migraine
CA2378428A1 (en) Use of cgrp antagonists and cgrp release inhibitors for combating menopausal hot flushes
WO2003045319A3 (en) Targeted therapeutics and uses thereof
GB2405336A (en) Cholinesterase inhibitors to prevent injuries caused by chemicals
EP1090635A3 (en) Use of ferulic acid for treating hypertension
IL144199A0 (en) Novel bretylium compositions and kits, and their use in preventing and treating cardiovascular conditions
EA200100871A1 (ru) Кристаллическая форма эплеренона, обладающая повышенной скоростью растворения